跳到正文
原文
Adam Feuerstein ✡️· @adamfeuerstein · X·· 5 天前AI 评分50
AI 导读

CADL将aglatimagene用于前列腺癌的BLA提交时间推迟至2027年中,公司正就提交事宜与FDA持续沟通。推迟原因是某些检测方法的优化所需时间,最终提交取决于与FDA沟通的结果。作者指出,公司此前曾多次承诺在2026年提交。

正文

$CADL delaying filing of BLA until the middle of 2027.

The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines associated with certain assay refinement, the Company currently plans to submit this BLA in the middle of 2027 pending the result of that dialogue.

So much for those repeated promises of a 2026 filing...

来源:Adam Feuerstein ✡️ · x.com